Hydrochlorothiazide.

What it does

HCTZ blocks the Na+-Cl− cotransporter (NCC) on the apical membrane of cells in the distal convoluted tubule of the kidney. Reabsorption of sodium and chloride from the urine is reduced, producing a moderate diuresis. The antihypertensive effect at low doses is partly through volume reduction and partly through other mechanisms not fully understood (changes in vascular tone over time).

HCTZ is less powerful as a diuretic than the loop diuretics (furosemide and others), and its diuretic effect plateaus at modest doses. For volume overload in heart failure, loop diuretics are preferred. For uncomplicated hypertension, low-dose thiazides are a long-standing first-line option in many guidelines. Sulfa diuretics covers the broader class.

What it is used for

Hypertension. Among the most prescribed antihypertensive drugs in the world. Often combined with an ACE inhibitor or ARB in fixed-dose formulations. Modern comparative evidence has raised questions about whether chlorthalidone (a related thiazide-like agent) may have advantages over HCTZ at typical clinical doses, but HCTZ remains widely used.

Edema. Mild peripheral edema in heart failure, often combined with a loop diuretic when needed for synergistic effect.

Kidney stone prevention. Thiazides reduce urinary calcium excretion, lowering the risk of recurrent calcium oxalate stones in selected patients.

Diabetes insipidus. Counterintuitively, thiazides reduce urine output in nephrogenic and central diabetes insipidus, through a complex mechanism involving volume contraction and altered tubular handling of water.

Common adverse effects

Most expected effects relate to the pharmacology:

Electrolyte changes — hypokalemia, hyponatremia (more common in older patients and at higher doses), occasionally hypomagnesemia. Hypercalcemia (paradoxical to a stone-preventing drug, but in a different way: serum calcium can rise because urinary loss is reduced).

Hyperuricemia and gout — thiazides raise serum urate and can precipitate gout.

Mild hyperglycemia — thiazides can modestly raise fasting blood glucose, particularly at higher doses.

Dyslipidemia — small increases in total cholesterol and triglycerides have been reported.

Photosensitivity — clinically important. HCTZ is among the more notable photosensitising drugs in routine prescribing. Photosensitivity covers the practical points.

Less common: rash (sometimes photosensitive in pattern), rare blood dyscrasias, rare pancreatitis, very rare interstitial nephritis.

Skin cancer risk: what the label now says

Long-term HCTZ use carries a documented association with non-melanoma skin cancer, and this is the one HCTZ safety topic that has genuinely changed in the last decade. A Danish nationwide study published in 2018 found a clear dose-response relationship: at high cumulative exposure the odds of squamous cell carcinoma were roughly four times those of non-users, rising to around sevenfold at the highest cumulative doses, with a smaller increase for basal cell carcinoma. The mechanism is thought to be photosensitisation acting over years rather than anything immunological.

Regulators acted on it. The European Medicines Agency issued a healthcare professional communication in October 2018 and required product information updates. Health Canada completed its review in January 2019. The U.S. FDA updated the label in August 2020, and the current U.S. prescribing information states that "hydrochlorothiazide is associated with an increased risk of non-melanoma skin cancer" and instructs prescribers to tell patients to protect their skin from the sun and undergo regular skin cancer screening.

Two clarifications, because both get muddled. First, this has nothing to do with sulfa allergy — it is a photocarcinogenicity signal, not a hypersensitivity one, and it applies equally to people with no allergy history at all. Second, the studies could not account for sun exposure itself, which matters given that HCTZ makes skin more sun-sensitive; some residual confounding is likely, which is part of why the absolute effect is presented as modest.

The sulfa allergy question

HCTZ contains the sulfonamide group but lacks an N4 arylamine. Published data show low cross-reactivity with sulfa antibiotic allergy. More on the data; common cross-reactivity questions covers the recurring patient queries directly.

Most prescribers will use HCTZ in patients with a documented mild sulfa antibiotic allergy. Patients with severe past reactions are managed individually. Photosensitivity reactions on HCTZ — distinct from cross-reactivity — should not be misinterpreted as evidence that "the sulfa is bothering me again."

Interactions

HCTZ interacts with several other drugs. Of clinical note: increased lithium levels (close monitoring required); additive electrolyte loss with other diuretics; reduced antihypertensive effect with NSAIDs; potentiation of digoxin toxicity through hypokalemia; increased calcium with vitamin D supplementation. The pharmacist's review at prescribing time matters.

See also

• Sulfa diureticsThe broader class.→
• Cross-reactivityWhat the data show.→
• PhotosensitivityWhy HCTZ is on the watch list.→
• Common cross-reactivity questionsBactrim and HCTZ, in detail.→